Advertisement

Canadian Anaesthetists’ Society Journal

, Volume 23, Issue 6, pp 624–635 | Cite as

The adenosine triphosphate (ATP) depletion test: Comparison with the caffeine contracture test as a method of diagnosing malignant hyperthermia susceptibility

  • Beverley A. Britt
  • Laszlo Endrenyi
  • Werner Kalow
  • Pearl L. Peters
Article

Summary

The adenosine triphosphate (ATP depletion ratio, which is the ratio [ATP] in skeletal muscle equilibrated with carbogen and 4% halothane for 30 minutes/

[ATP] in skeletal muscle equilibrated with carbogen alone for 30 minutes is less than normal in most but not in all rigid MHS patients. The ratio is normal in non-rigid MHS patients. This diagnostic tool is, therefore, useful in the diagnosis of rigid MH. It is not, however, such a sensitive diagnostic parameter as the caffeine contracture test.

Keywords

Caffeine Halothane Malignant Hyperthermia Carbogen Muscle Fascicle 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Résumé

Le rapport de 1a déplétion en adénosine triphosphate, qui est le rapport entre : (ATP) dans le muscle squelettique mis en équilibre avec du carbogène et 4% d’Halothane durant 30 minutes/ (ATP) dans le muscle squelettique mis en équilibre avec du carbogène durant 30 minutes est plus petit que normalement chez la plupart des patients qui ont une susceptibilité à la forme rigide de l’hyperthermie maligne, mais non chez tous. Ce rapport est normal dans la forme non rigide. Il s’agit donc d’un examen utile dans le diagnostic de la forme rigide de l’hyperthermie maligne. Cet examen n’est toutefois pas aussi sensible que celui de la contraction musculaire à la caféine.

References

  1. 1.
    Harrison, G.G., Saunders, S.J., Biebuyck, J.F., Hickman, R., Dent, D.M., Weaver, V., &Terblanche, J. Anaesthetic-induced malignant hyperpyrexia and a method for its prediction. Brit. J. Anaesth.41: 844 (1969).PubMedCrossRefGoogle Scholar
  2. 2.
    Boehringer Kit, Catalogue #15979 TWAC.Google Scholar
  3. 3.
    Nelson, T.E., Jones, E.W., Venable, J.H., &Kerr, D.D. Malignant hyperthermia of Poland China swine. Studies of a myogenic etiology. Anaesthesiology36: 52 (1972).CrossRefGoogle Scholar
  4. 4.
    Isaacs, H. &Heffron, J.J.A. Morphological and biochemical defects in muscles of human carriers of the malignant hyperthermia syndrome. Brit. J. Anaesth.47: 475 (1975).PubMedCrossRefGoogle Scholar
  5. 5.
    Isaacs, H., Heffron, J.J.A., &Pickering, A. Further studies in malignant hyperpyrexia. South African Med. J.49: 282 (1975).Google Scholar
  6. 6.
    Lamphrecht, W. &Stein, P. Creatine phosphate.In Methods of Enzymatic Analysis (ed. H.V. Bergmeyere), New York, Academic Press, p. 610.Google Scholar
  7. 7.
    Kalow, W., Britt, B.A., Terreau, M.E., &Haist, C. Metabolic error of muscle metabolism after recovery from malignant hyperthermia. Lancet ii: 895 (1970).CrossRefGoogle Scholar
  8. 8.
    Kalow, W., Britt, B.A., &Richter, A. The caffeine test of isolated human muscle in relation to malignant hyperthermia. In press, 1976.Google Scholar
  9. 9.
    Britt, B.A. Malignant hyperthermia - an investigation of three patients. Ann Roy. Coll. Surg.Eng.48:73 (1971).PubMedGoogle Scholar
  10. 10.
    Britt, B.A., Kalow, W., Gordon, A., Humphrey, J.G., &Rewcastle, N.B. Malignant hyperthermia: an investigation of five patients. Canad. Anaesth. Soc. J.20: 431 (1973).PubMedGoogle Scholar
  11. 11.
    Ellis, F.R., Keaney, N.P., Harriman, D.G.F., Sumner, D.W., Kyei-Mensah, K., Tyrrell, J.H., Hargreaves, J.B., Parikh, R.K., &Mulrooney, P.L. Screening for malignant hyperpyrexia. Brit. Med. J.3: 559 (1972).PubMedCrossRefGoogle Scholar
  12. 12.
    Ellis, F.R., Keaney, N.P., &Harriman, D.G.F. Histopathological and neuropharmacological aspects of malignant hyperpyrexia. Proc. Roy. Soc. Med.66: 66 (1973).PubMedGoogle Scholar
  13. 13.
    Ellis, F.R. &Harriman, D.G.F. A new screening test for susceptibility to malignant hyperpyrexia. Brit. J. Anaesth.45: 638 (1973).PubMedCrossRefGoogle Scholar
  14. 14.
    Ellis, F.R., Clarke, I.M.C., Appleyard, T.N., &Dinsdale, R.C.W. Malignant hyperpyrexia induced by nitrous oxide and treated with dexamethasone. Brit. Med. J.4: 270 (1974).PubMedGoogle Scholar
  15. 15.
    Mitchelson, K.R. Ph.D. Thesis - Investigations on malignant hyperpyrexia (1974).Google Scholar
  16. 16.
    Moulds, R.F.W. &Denborough, M.A. Procaine in malignant hyperpyrexia. Brit. Med. J.4: 526 (1972).PubMedGoogle Scholar
  17. 17.
    Moulds, R.F.W. &Denborough, M.A. Biochemical basis of malignant hyperpyrexia. Brit. Med. J.2: 245 (1974).PubMedGoogle Scholar
  18. 18.
    Denborough, M.A., Dennett, X., &Anderson, R.McD. Central-core disease and malignant hyperpyrexia. Brit. Med. J.1: 272 (1973).PubMedGoogle Scholar
  19. 19.
    Schmitt, H.P., Simmendinger, HJ., Wagner, H., Volk, B., Busing, CM., &Stenzell, M. Severe morphological changes in skeletal muscles of a five-month-old infant dying from an anesthetic complication with general muscle rigidity. Syndrome of “malignant hyperpyrexia” without hyperthermia? Neuropadiatrie6: 102 (1975).CrossRefGoogle Scholar
  20. 20.
    LaCour, D., Juul-Jensen, P., &Reske-Nielsen, E. Malignant hyperthermia during anaesthesia. Acta anaesth. scand.15: 299 (1971).PubMedCrossRefGoogle Scholar
  21. 21.
    LaCour, D., Juul-Jensen, P., & Reske-Nielsen, E. Central and peripheral mechanisms in malignant hyperthermia.In International Symposium on Malignant Hyperthermia (ed. Gordon, Britt and Kalow), Charles C. Thomas, Springfield, p. 380 (1973).Google Scholar
  22. 22.
    Reske-Nielsen, E., Haase, J., &Kelstrup, J. Malignant hyperthermia in a family. The neurophysiological and light microscopical study of muscle biopsies of healthy members. Acta path, microbiol. scand.83: 645 (1975).Google Scholar
  23. 23.
    Reske-Nielsen, E., Haase, J., &Kelstrup, J. Malignant hyperthermia in a family. The ultrastructure of muscle biopsies of healthy members. Acta path. microbiol. scand.83: 651 (1975).Google Scholar
  24. 24.
    Reske-Nielsen, E. Ultrastructure of human muscle in malignant hyperthermia. Acta path. microbiol. scand. 81; 585 (1973).Google Scholar
  25. 25.
    Britt, B.A., Endrenyi, L., Peters, P.L., Kwong, F.H-F., &Kadijevic, L. Screening of malignant Hyperthermic susceptible families by CPK measurement and other clinical investigations. Canad. Anaesth. Soc. J.23: 263 (1976).PubMedCrossRefGoogle Scholar
  26. 26.
    King, J.P., Denborough, M.A., &Zaph, P.W. Inheritance of malignant hyperpyrexia. Lancet i: 365 (1972).CrossRefGoogle Scholar
  27. 27.
    Denborough, M.A. The muscular dystrophy-malignant hyperpyrexia syndrome. Royal Melbourne Hospital Grand Rounds, Victoria, Australia.Google Scholar
  28. 28.
    Denborough, M.A., King, J.O., Ebeling, P., &Zapf, P. Myopathy and malignant hyperpyrexia. Lancet i: 1138 (1970).CrossRefGoogle Scholar
  29. 29.
    Britt, B.A. &Kalow, W. Malignant hyperthermia: a statistical review, Canad. Anaesth. Soc. J.17: 293 (1970).PubMedCrossRefGoogle Scholar
  30. 30.
    Harriman, D.G.F. &Ellis, F.R. Structural and neuropharmacological aspects of malignant hyperpyrexia. J. Pathol.107: 9 (1972).CrossRefGoogle Scholar
  31. 31.
    Harriman, D.G.F. &Ellis, F.R. Central-core disease and malignant hyperpyrexia. Brit. Med. J.1: 545 (1973).PubMedGoogle Scholar
  32. 32.
    Harriman, D.G.F., Sumner, D.W., &Ellis, F.R. Malignant hyperpyrexia myopathy. Quarterly J. Med. XLII: 639 (1973).Google Scholar
  33. 33.
    Steers, A.J.W., Tallack, J.A., &Thompson, D.E.A. Fulminating hyperpyrexia during anaesthesia in a member of a myopathic family. Brit. Med. J.2: 341 (1970).PubMedGoogle Scholar
  34. 34.
    Thompson, D.E.A. &Tallack, J.A. Coexistent muscle disease and malignant hyperpyrexia.In International Symposium on Malignant Hyperthermia (ed. Gordon, Britt and Kalow), Charles C. Thomas, Springfield, p. 309 (1973).Google Scholar
  35. 35.
    Denborough, M.A., Hudson, M.C., Forster, J.F.A., Carter, N.G., &Zapf, P. Biochemical changes in malignant hyperpyrexia. Lancet ii: 1137 (1970).CrossRefGoogle Scholar
  36. 36.
    Denborough, M.A., Forster, J.F.A., Hudson, M:C, Carter, N.G., & Zapf, P. Malignant hyperpyrexia - a serious, preventable complication of general anaesthesia.Google Scholar
  37. 37.
    Moulds, R.F.W. &Denborough, M.A. Identification of susceptibility to malignant hyper-pyrexia. Brit. Med. J.2: 241 (1974).PubMedGoogle Scholar
  38. 38.
    Larard, D.G., Rice, C.P., Robinson, R.W., Spencer, R.W., &Westhead, R.A. Malignant hyperthermia: a study of an affected family. Brit. J. Anaesth.44: 93 (1972).PubMedCrossRefGoogle Scholar
  39. 39.
    Parikh, R.K. &Thomson, W.H.S. Malignant hyperthermia: a fatal case and his family. Brit. J. Anaesth.44: 742 (1972).PubMedCrossRefGoogle Scholar
  40. 40.
    Kyei-Mensah, K., Lockwood, R., Tyrell, J.H., &Willett, I.H. Malignant hyperpyrexia: a study of a family. Brit. J. Anaesth.43: 811 (1971).PubMedCrossRefGoogle Scholar
  41. 41.
    Kyei-Mensah, K., Tyrell, J.H., &Summer, D.W. Clinical and genetic aspects of malignant hyperpyrexia. Proc. Roy. Soc. Med.66: 63 (1973).PubMedGoogle Scholar
  42. 42.
    Zsigmond, E.K., Starkweather, W.H., Duboff, G.S., &Flynn, K. CPK and malignant hyperthermia. Anesth. Analg.51: 220 (1972).PubMedGoogle Scholar
  43. 43.
    LaCour, D., Juul-Densen, P., &Reske-Nielsen, E. Malignant hyperthermia during anaesthesia. Acta anaesth, Scandinav.15: 299 (1971).CrossRefGoogle Scholar
  44. 44.
    Britt, B.A., Kwong, F.H.-F., &Endrenyi, L. The clinical and laboratory features of malignant hyperthermia management - a review.In Malignant Hyperthermia Syndrome (ed. Henschel, E.O.), Appleton-Century-Crofts (in press, 1976).Google Scholar
  45. 45.
    Berman, M.C. &Kench, J.E. Biochemical features of malignant hyperthermia in landrace pigs.In International Symposium on Malignant Hyperthermia (ed. Gordon, Britt and Kalow), Charles C. Thomas, Springfield, p. 287 (1973).Google Scholar
  46. 46.
    Denborough, M.A., Hird, F.J.R., King, J.O., Marginson, M.A., Mitchelson, K.R., Nay-ler, W.G., Rex, M.A., Zapf, P., &Condron, R.J. Mitochondrial and other studies in Australian landrace pigs affected with malignant hyperthermia.In International Symposium on Malignant Hyperthermia (ed. Gordon, Britt and Kalow), Charles C. Thomas, Springfield, p, 229 (1973).Google Scholar
  47. 47.
    Harrison, G.G. Recent advances in the understanding of anaesthetic-induced malignant hyperpyrexia. Anaesthetist22: 373 (1973).Google Scholar
  48. 48.
    Strobel, G.E. Aetiology and pathophysiology of malignant hyperthermia.In Malignant Hyperthermia Syndrome (ed. Henschel, E.O.), Appleton-Century-Crofts (in press, 1976).Google Scholar
  49. 49.
    Britt, B.A, Recent advances in malignant hyperthermia. Anesth. Analg.51: 841 (1972).PubMedCrossRefGoogle Scholar
  50. 50.
    Britt, B.A. Malignant hyperthermia: a pharmacogenetic disease of skeletal and cardiac muscle. New England J. Med.74: 1140 (1974).CrossRefGoogle Scholar
  51. 51.
    Britt, B.A. Malignant hyperthermia.In Cohen, P.J. (ed.). Metabolic Aspects of Anesthesia (Clinical Anesthesia V.11/1),F.A. Davis Co., Philadelphia (1975).Google Scholar

Copyright information

© Canadian Anesthesiologists 1976

Authors and Affiliations

  • Beverley A. Britt
    • 1
  • Laszlo Endrenyi
    • 1
    • 2
  • Werner Kalow
    • 1
    • 2
  • Pearl L. Peters
    • 1
    • 2
  1. 1.Departments of Anaesthesia and PharmacologyUniversity of TorontoToronto
  2. 2.Department of PharmacologyUniversity of TorontoToronto

Personalised recommendations